Please use this identifier to cite or link to this item: http://hdl.handle.net/2440/124889
Citations
Scopus Web of Science® Altmetric
?
?
Type: Journal article
Title: Decatenation checkpoint-defective melanomas are dependent on PI3K for survival
Author: Brooks, K.
Ranall, M.
Spoerri, L.
Stevenson, A.
Gunasingh, G.
Pavey, S.
Meunier, F.
Gonda, T.
Gabrielli, B.
Citation: Pigment Cell and Melanoma Research, 2014; 27(5):813-821
Publisher: Wiley
Issue Date: 2014
ISSN: 1755-1471
1755-148X
Statement of
Responsibility: 
Kelly Brooks, Max Ranall, Loredana Spoerri, Alex Stevenson, Gency Gunasingh, Sandra Pavey, Fred Meunier, Thomas J. Gonda, Brian Gabriell
Abstract: Melanoma cell lines are commonly defective for the G2-phase cell cycle checkpoint that responds to incomplete catenation of the replicated chromosomes. Here, we demonstrate that melanomas defective for this checkpoint response are less sensitive to genotoxic stress, suggesting that the defective cell lines compensated for the checkpoint loss by increasing their ability to cope with DNA damage. We performed an siRNA kinome screen to identify kinases responsible and identified PI3K pathway components. Checkpoint-defective cell lines were three-fold more sensitive to small molecule inhibitors of PI3K. The PI3K inhibitor PF-05212384 promoted apoptosis in the checkpoint-defective lines, and the increased sensitivity to PI3K inhibition correlated with increased levels of activated Akt. This work demonstrates that increased PI3K pathway activation is a necessary adaption for the continued viability of melanomas with a defective decatenation checkpoint.
Keywords: Decatenation checkpoint; melanoma; synthetic lethality; PI3K
Rights: © 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
RMID: 1000015611
DOI: 10.1111/pcmr.12268
Grant ID: http://purl.org/au-research/grants/nhmrc/1029260
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.